NRC
VRTX icon

New Republic Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

New Republic Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$238K Sell
532
-293
-36% -$137K 0.08% 209
2025
Q4 		$374K Buy
+825
New +$356K 0.1% 184
2024
Q3 		– Sell
-626
Closed -$293K – 266
2024
Q2 		$293K Buy
+626
New +$272K 0.15% 125

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

New Republic Capital's VRTX Position: Q1 2026 in Review

New Republic Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 36% in Q1 2026, selling an estimated $137K and leaving 532 shares worth $238K. The position accounts for 0.08% of the portfolio, ranked #209.

New Republic Capital first reported a position in VRTX in Q2 2024 and has held it in 3 quarters since. The position peaked at $374K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • New Republic Capital held 532 shares of Vertex Pharmaceuticals worth $238K as of Q1 2026.
  • New Republic Capital sold 293 Vertex Pharmaceuticals shares in Q1 2026, an estimated $137K.
  • Vertex Pharmaceuticals made up 0.08% of New Republic Capital's portfolio in Q1 2026, its #209 holding.
  • New Republic Capital first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 3 quarters since.
  • New Republic Capital's Vertex Pharmaceuticals position peaked at $374K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on New Republic Capital's 13F filing for Q1 2026, filed 1 May 2026.